Kidney Disease

References

Andreotti, F., Burzotta, F., Mazza, A., Manzoli, A., Robinson, K., Maseri, A. Homocysteine and arterial occlusive disease: a concise review. Cardiologia 1999 Apr; 44(4): 341-5.

Aukema, H.M., Housini, I., Rawling, J.M. Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. J. Am. Soc. Nephrol. 1999 Feb; 10(2): 300-8.

Bacallao, R.L., Carone, F.A. Recent advances in the understanding of polycystic kidney disease. Curr. Opin. Nephrol. Hypertens. 1997 Jul; 6(4): 377-83.

Bagchi, D., Bagchi, M., Stohs, S.J., Das, D.K., Ray, S.D., Kuszynski, C.A., Joshi, S.S., Pruess, H.G. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology 2000 Aug 7; 148(2-3): 187-97.

Barak, A.J., Beckenhauer, H.C., Tuma, D.J. Betaine, ethanol, and the liver: a review. Alcohol 1996; 13: 395-8.

Boldt, J., Brosch, C., Piper, S.N., Suttner, S. et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit. Care Med. 2001 May; 29(5): 952?8.

Bostom, A.G., Shemin, D., Lapane, K.L., Hume, A.L., Yoburn, D., Nadeau, M.R., Bendich, A., Selhub, J., Rosenberg, I.H. High-dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 1996 Jan; 49(1): 147-52.

Brkljacic, B. et al. Renal vascular resistance in autosomal dominant polycystic kidney disease. Evaluation with color Doppler ultrasound. Acta Radiol. 1997 Sep; 38(5): 840-6.

Chambers, S.T. Betaines: their significance for bacteria and the renal tract. Clin. Sci. 1995; 88(1): 25-7.

Chapman, A.B., Johnson, A.M., Rainguet, S., Hossack, K., Gabow, P., Schrier, R.W. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1997 Aug; 8(8): 1292-7.

Chauveau, P., Chadefaux, B., Coude, M., Aupetit, J., Kamoun, P., Jungers, P. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner. Electrolyte Metab. 1996; 22(1-3): 106-9.

Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B., Graham, I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 1991 Apr 25; 324(17): 1149-55.

Clermont, G., Lecour, S., Lahet, J., Siohan, P., Vergely, C., Chevet, D., Rifle, G., Rochette, L. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc. Res. 2000 Aug 18; 47(3): 618-23.

Dierkes, J. et al. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin. Nephrol. 1999 Feb; 51(2): 108-15.

Ettinger, B. et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J. Urol. 1997 Dec; 158(6): 2069-73.

Fored, C.M., Ejerblad, E., Lindblad, P., Fryzek, J.P., Dickman, P.W., Signorello, L.B., Lipworth, L., Elinder, C.G., Blot, W.J., McLaughlin, J.K., Zack, M.M., Nyren, O. Acetaminophen, aspirin, and chronic renal failure. N. Engl. J. Med. 2001 Dec 20; 345(25): 1801-8; comment, N. Engl. J. Med. 2001 Dec 20; 345(25): 1844-6.

Franconi, F., Bennardini, F., Mattana, A. et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am. J. Clin. Nutr. 1995; 61: 1115-9.

Friedman, A.N., Bostom, A.G., Selhub, J., Levey, A.S., Rosenberg, I.H. The kidney and homocysteine metabolism. J. Am. Soc. Nephrol. 2001 Oct; 12(10): 2181-9.

Fukaya, H., Kanno, H. Experimental studies of the protective effect of ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats. Nippon Jibinkoka Gakkai Kaiho 1999 Jul; 102(7): 907-17 (in Japanese).

Gahl, W.A., Bernardini, I., Chen, S., Kurtz, D., Horvath, K. The effect of oral betaine on vertebral body bone density in pyridoxine-non-responsive homocystinuria. J. Inherit. Metab. Dis. 1988; 11: 291-8.

Glanze, W.D. The Mosby Medical Encyclopedia, Revised Edition 1996. St. Louis, MO: C.V. Mosby.

Grantham, J.J. Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int. Suppl. 1997 Dec; 63: S93-S97.

Grantham, J.J., Nair, V., Winklhofer, F. Cystic disease of the kidney. In Brenner & Rector's The Kidney, Volume 2, Sixth Edition 2000, pp. 1699-1730. Philadelphia, PA: W.B. Saunders.

Hahn, S. et al. Glomerulosclerosis in the remnant kidney rat is modulated by dietary
alpha-tocopherol. J. Am. Soc. Nephrol. 1998 Nov; 9(11): 2089-95.

Herrmann, W., Schorr, H., Geisel, J., Riegel, W. Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin. Chem. Lab. Med. 2001 Aug; 39(8): 739-46.

Hoffer, L.J., Robitaille, L., Elian, K.M., Bank, I., Hongsprabhas, P., Mamer, O.A. Plasma reduced homocysteine concentrations are increased in end-stage renal disease. Kidney Int. 2001 Jan; 59(1): 372-7.

Joosten, E., Lesaffre, E., Riezler, R., Ghekiere, V., Dereymaeker, L., Pelemans, W., Dejaeger, E. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J. Gerontol. A Biol. Sci. Med. Sci. 1997 Mar; 52(2): M76-M79.

Kalinowski, M. et al. Effects of L-carnitine on erythropoiesis and blood platelet aggregation in patients with chronic renal failure treated with hemodialysis. Pol. Merkuriusz. Lek. 1999 Feb; 6(32): 76-8.

LaPorte, J. et al. Kidney stones. How to identify the cause and prevent recurrence. Postgrad. Med. 1990 Apr; 87(5): 219-23, 226.

Levin, A., Stevens, L., McCullough, P.A. Cardiovascular disease and the kidney: tracking a killer in chronic kidney disease. Postgrad. Med. 2002; 111(4): 53-60.

Licinio, J., Wong, M.L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 1999 Jul; 4(4): 317?27.

Li Kam Wa, T.C. Ambulatory blood pressure in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 1997 Oct; 12(10): 2075-80.

Lingens, N., Freund, M., Seeman, T., Witte, K., Lemmer, B., Scharer, K. Circadian blood pressure changes in untreated children with kidney disease and conserved renal function. Acta Paediatr. 1997 Jul; 86(7): 719-23.

Marangon, K., O'Byrne, D., Devaraj, S., Jialal, I. Validation of an immunoassay for measurement of plasma total homocysteine. Am. J. Clin. Pathol. 1999 Dec; 112(6): 757-62.

McCaddon, A., Davies, G., Hudson, P., Tandy, S., Cattell, H. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 1998 Apr; 13(4): 235-9.

McCully, KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 1969 Jul; 56(1): 111-28.

McGregor, D., Shand, B., Lynn, K. A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron 2000 Jul; 85(3): 215-20.

Merta, M., Stekrova, J., Zidovska, J., Vorsilkova, M., Walterova, J., Kapras, J., Alanova, M., Raskova, D., Gaillyova, R., Archmanova, E., Rysava, R. DNA diagnosis and clinical manifestations of autosomal dominant polycystic kidney disease. Folia Biol. 1997; 43(5): 201-4.

Miller-Hjelle, M.A. et al. Polycystic kidney disease: an unrecognized emerging infectious disease? Emerg. Infect. Dis. 1997 Apr-Jun; 3(2): 113-27.

Mukoyama, A., Ushijima, H., Nishimura, S., Koike, H., Toda, M., Hara, Y., Shimamura, T. Inhibition of rotavirus and enterovirus infections by tea extracts. Jpn. J. Med. Sci. Biol. 1991 Aug; 44(4): 181-6.

Naidu, M.U., Shifow, A.A., Kumar, K.V., Ratnaker, K.S. Ginkgo biloba extract ameliorates gentamicin-induced nephrotoxicity in rats. Phytomedicine 2000 Jun; 7(3): 191-7.

National Kidney Foundation. Millions of Americans May Be at Risk for Kidney Disease: Simple Blood Tests Can Detect Your Risk 2001a Feb 26. New York: National Kidney Foundation (www.kidney.org).

National Kidney Foundation. Nutrition and Chronic Kidney Disease 2001b. New York: National Kidney Foundation.

National Kidney Foundation. Phosphorous and Renal Diet 2001c. New York: National Kidney Foundation.

National Kidney Foundation. Potassium and Renal Diet 2001d. New York: National Kidney Foundation.

National Kidney Foundation. Vitamins and Minerals in Kidney Disease 2001e. New York: National Kidney Foundation.

National Kidney and Urologic Diseases Information Clearinghouse. What Are Kidney Stones? 1998. Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse/ National Institute of Diabetes & Digestive & Kidney Diseases.

Navarro, J.F., Mora, C., Rivero, A., et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am. J. Kidney Dis. 1999a Mar; 33(3): 458?63.

Navarro, J.F., Mora, C., Garcia, J. et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand. J. Urol. Nephrol. 1999b Apr; 33(2): 121?5.

NCHS. Current Estimates from the National Health Interview Survey, 1996. 1999 Oct, Series 10(200). Atlanta, GA: National Center for Health Statistics/Centers for Disease Control and Prevention/U.S. Department of Health and Human Services.

NIDDK. What Are Kidney Stones? 1998. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (www.niddk.nih.gov).

NIDDK. Kidney Diseases Dictionary Index 1999. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (www.niddk.nih.gov).

NIDDK. Anemia in Kidney Disease and Dialysis 2001a Apr. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (www.niddk.nih.gov).

NIDDK. Kidney and Urologic Diseases Statistics for the United States 2001b Dec. Bethesda, MD: National Institute of Diabetes & Digestive & Kidney Diseases/National Institutes of Health (www.niddk.nih.gov).

NORD. Renal Disease Overview 2002. Universal City, CA: National Organization for Renal Disease (www.stop-ersd.org).

Ogborn, M.R., Nitschmann, E., Weiler, H.A., Bankovic-Calic, N. Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int. 2000 Jan; 57(1): 159-66.

Ohgitani, S., Fujita, T. Calcium decreases urinary oxalate. Nippon Ronen Igakkai Zasshi 2000 Oct; 37(10): 805-10 (in Japanese).

Ranich, T., Bhathena, S.J., Velasquez, M.T. Protective effects of dietary phytoestrogens in chronic renal disease. J. Ren. Nutr. 2001 Oct; 11(4): 183-93.

Ray, S.D., Patel, D., Wong, V., Bagchi, D. In vivo protection of DNA damage associated apoptocic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract. Res. Commun. Mol. Pathol. Pharmacol. 2000; 107(1-2): 137-66.

Robinson, K., Gupta, A., Dennis, V., Arheart, K., Chaudhary, D., Green, R., Vigo, P., Mayer, E.L., Selhub, J., Kutner, M., Jacobsen, D.W. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996 Dec 1; 94(11): 2743-8.

Rodgers, A.L. et al. Effect of mineral water containing calcium and magnesium on calcium oxalate urolithiasis risk factors. Urol. Int. 1997; 58(2): 93-9.

Sadava, D., Luo, P.W., Casper, J. Induction of renal damage in rats by a diet deficient in antioxidants. Nutr. Res. 1996; 16(9): 1607-12.

Saionji, K. et al. Homeostasis of antioxidant status in hemodialysis patients. Rinsho Byori 1999 May; 47(5): 461-6 (in Japanese).

Sakurauchi, Y. et al. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. Am. J. Kidney Dis. 1998 Aug; 32(2): 258-64.

Selhub, J. Homocysteine metabolism. Annu. Rev. Nutr. 1999; 19: 217-46.

Selhub, J., Jacques, P.F., Bostom, A.G., D'Agostino, R.B., Wilson, P.W., Belanger, A.J., O'Leary, D.H., Wolf, P.A., Schaefer, E.J., Rosenberg, I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 1995 Feb 2; 332(5): 286-91.

Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., D'Agostino, R.B., Wilson, P.W., Wolf, P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002 Feb 14; 346(7): 476-83.

Sessa, A., Ghiggeri, G.M., Turco A.E. Autosomal dominant polycystic kidney disease: clinical and genetic aspects. J. Nephrol. 1997 Nov-Dec; 10(6): 295-310.

Sloan, R.S., Kastan, B., Rice, S.I., Sallee, C.W., Yuenger, N.J., Smith, B., Ward, R.A., Brier, M.E., Golper, T.A. Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation. Am. J. Kidney Dis. 1998 Aug; 32(2): 265-72; comment, Am. J. Kidney Dis. 1999 Aug; 34(2): 400-1.

Stampfer, M.J., Malinow, M.R., Willett, W.C., Newcomer, L.M., Upson, B., Ullmann, D., Tishler, P.V., Hennekens, C.H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. JAMA 1992 Aug 19; 268(7): 877-81.

Stampfer, M.J., Malinow, M.R. Can lowering homocysteine levels reduce cardiovascular risk? N. Engl. J. Med. 1995 Feb 2; 332(5): 328-9.

Suliman, M.E., Lindholm, B., Barany, P., Bergstrom, J. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. Clin. Chem. Lab. Med. 2001 Aug; 39(8): 734-8.

Suresh Babu, P., Srinivasan, K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol. Cell. Biochem. 1998 Apr; 181(1-2): 87-96.

Takei, K., Ito, H., Masai, M., Kotake, T. Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. Urol. Int. 1998; 61(3): 192-5.

Tomobe, K., Philbrick, D.J., Ogborn, M.R., Takahashi, H., Holub, B.J. Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease. Am. J. Kidney Dis. 1998 Jan; 31(1): 55-61.

Trachtman, H., Sturman, J.A. Taurine: a therapeutic agent in experimental kidney disease. Amino Acids 1996; 11(1): 1-13.

Tucker, K.L., Mahnken, B., Wilson, P.W., Jacques, P., Selhub, J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA 1996 Dec 18; 276(23): 1879-85.

Ueland, P.M., Ulvik, R.J., Refsum, H. Routine determination of homocysteine in plasma. A new and improved possibility for risk evaluation and diagnosis of common diseases. Tidsskr. Nor. Laegenforen. 1992 Sep 30; 112(23): 2977-80 (in Norwegian).

Umegaki, K., Shinozuka, K., Watarai, K., Takenaka, H., Yoshimura, M., Daohua, P., Esashi, T. Gingo biloba extract attenuates the development of hypertension in dioxycorticosterone acetate-salt hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2000 Apr; 27(4): 277-82.

USRDS. USRDS 2001 Annual Data Report 2001 Nov 21. U.S. Renal Data System. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health (www.usrds.org).

Van der Meide, P.H., Schellekens, H. Cytokines and the immune response. Biotherapy 1996; 8(3-4): 243?9.

van Guldener, C., Janssen, M.J., de Meer, K. et al. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. J. Intern. Med. 1999; 245: 175-83.

van Guldener, C., Stehouwer, CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin. Thromb. Hemost. 2000; 26(3): 281?9.

Velasquez, M.T., Bhathena, S.J. Dietary phytoestrogens: a possible role in renal disease protection. Am. J. Kidney Dis. 2001 May; 37(5): 1056-68.

Venkatesan, N., Punithavathi, D., Arumugam, V. Curcumin prevents adriamycin nephrotoxicity in rats. Br. J. Pharmacol. 2000 Jan; 129(2): 231-4.

Verhoef, P., Stampfer, M.J., Buring, J.E., Gaziano, J.M., Allen, R.H., Stabler, S.P., Reynolds, R.D., Kok, F.J., Hennekens, C.H., Willett, W.C. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am. J. Epidemiol. 1996 May 1; 143(9): 845-59.

Walser, M. et al. Can renal replacement be deferred by a supplemented very low protein diet? J. Am. Soc. Nephrol. 1999 Jan; 10(1): 110-6.

Wanic-Kossowska, M., Bombicki, K., Koziol, L., Czarnecki, R. Levels of L-carnitine in serum of patients with chronic renal failure treated by hemodialysis (HD). Pol. Arch. Med. Wewn. 1998 Apr; 99(4): 314-22.

Wardle, E.N. Antioxidants in the prevention of renal disease. Renal Fail. 1999 Nov; 21(6): 581-91.

Welch, G.N., Loscalzo, J. Homocysteine and atherothrombosis. N. Engl. J. Med. 1998 Apr 9; 338(15): 1042-50.

Wendel, U., Bremer, H.J. Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Eur. J. Pediatr. 1984; 142: 147-50.

Wilcken, D.E.L., Wilcken, B., Dudman, N.P.B., Tyrrell, P.A. Homocystinuria?the effects of betaine in the treatment of patients not responsive to pyridoxine. N. Engl. J. Med. 1983; 309: 448-53.

Williams, C.P., Child, D.F., Hudson, P.R., Davies, G.K., Davies, M.G., John, R., Anandaram, P.S., De Bolla, A.R. Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study. J. Clin. Pathol. 2001 Jan; 54(1): 54-62.

Wratten, M.L. et al. Haemolipodialysis. Blood Purif. 1999; 17(2-3): 127-33.

Yokozawa, T., Chung, H.Y., He, L.Q., Oura, H. Effectiveness of green tea tannin on rats with chronic renal failure. Biosci. Biotechnol. Biochem. 1996 Jun; 60(6): 1000-5.

Yokozawa, T., Nakagawa, T., Lee, K.I., Cho, E.J., Terasawa, K., Takeuchi, S. Effects of green tea tannin on cisplatin-induced nephropathy in LLC-PK1 cells and rats. J. Pharm. Pharmacol. 1999 Nov; 51(11): 1325-31.

Yuan, C.F., Lin, C.Y., Chen, T.W., Yang, M.L., Ng, H.T. Linkage analysis of families with autosomal dominant polycystic kidney disease by KG8-CA marker. Zhonghua Yi Xue Za Zhi 1997 Sep; 60(3): 125-9.